Trial · NCT02402309

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309, Phase 2, Completed, Aldeyra Therapeutics, Inc.; results first posted 2022-12-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS). Trials, record NCT02402309. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02402309

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
NCT number: NCT02402309
Status: Completed
Phases: Phase 2
Enrollment: 12 participants, actual
Lead sponsor: Aldeyra Therapeutics, Inc.
Conditions: Sjögren-Larsson Syndrome
Interventions: Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
First posted: 2015-03-30
Last updated: 2022-12-13
Results first posted: 2022-12-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Experiencing a Serious Adverse Event (SAE).	The safety assessment period is approximately 9 weeks.
Primary	Number of Participants Experiencing an Adverse Event Leading to Discontinuation.	The safety assessment period is approximately 9 weeks.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants Experiencing a Serious Adverse Event (SAE).	The safety assessment period is approximately 9 weeks.		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants Experiencing an Adverse Event Leading to Discontinuation.	The safety assessment period is approximately 9 weeks.		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Units
Number of Participants Experiencing a Serious Adverse Event (SAE).	Topical NS2 1% Dermatologic Cream	Participants
Number of Participants Experiencing a Serious Adverse Event (SAE).	Topical Vehicle Dermatologic	Participants
Number of Participants Experiencing an Adverse Event Leading to Discontinuation.	Topical NS2 1% Dermatologic Cream	Participants
Number of Participants Experiencing an Adverse Event Leading to Discontinuation.	Topical Vehicle Dermatologic	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Topical NS2 1% Dermatologic Cream	6
Overall Study	STARTED	Topical Vehicle Dermatologic	6
Overall Study	COMPLETED	Topical NS2 1% Dermatologic Cream	6
Overall Study	COMPLETED	Topical Vehicle Dermatologic	6
Overall Study	NOT COMPLETED	Topical NS2 1% Dermatologic Cream	0
Overall Study	NOT COMPLETED	Topical Vehicle Dermatologic	0

Source ClinicalTrials.gov

Adverse events36

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Pruritus	Skin and subcutaneous tissue disorders	Topical NS2 1% Dermatologic Cream	2	6
other	Pruritus	Skin and subcutaneous tissue disorders	Topical Vehicle Dermatologic	0	6
other	Blister	Skin and subcutaneous tissue disorders	Topical NS2 1% Dermatologic Cream	0	6
other	Blister	Skin and subcutaneous tissue disorders	Topical Vehicle Dermatologic	1	6
other	Rash	Skin and subcutaneous tissue disorders	Topical NS2 1% Dermatologic Cream	0	6
other	Rash	Skin and subcutaneous tissue disorders	Topical Vehicle Dermatologic	1	6
other	Skin ulcer	Skin and subcutaneous tissue disorders	Topical NS2 1% Dermatologic Cream	0	6
other	Skin ulcer	Skin and subcutaneous tissue disorders	Topical Vehicle Dermatologic	1	6
other	Nasopharyngitis	Infections and infestations	Topical NS2 1% Dermatologic Cream	0	6
other	Nasopharyngitis	Infections and infestations	Topical Vehicle Dermatologic	1	6

1 to 10 of 36Source ClinicalTrials.gov

See all 36 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Topical NS2 1% Dermatologic Cream	0	6
Total, all-cause mortality	Topical Vehicle Dermatologic	0	6
Total, other adverse events	Topical NS2 1% Dermatologic Cream	5	6
Total, other adverse events	Topical Vehicle Dermatologic	3	6
Total, serious adverse events	Topical NS2 1% Dermatologic Cream	0	6
Total, serious adverse events	Topical Vehicle Dermatologic	0	6

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: Number of Participants Experiencing a Serious Adverse Event (SAE).	Trial comparisons
Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: Number of Participants Experiencing an Adverse Event Leading to Discontinuation.	Trial comparisons
Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: deaths from any cause	Trial comparisons
Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02402309

GET https://conductscience.org/api/trials/v1/NCT02402309/events?page=2

API reference For AI assistants